Ligand, Janssen Enter R&D Deal

Date : 12/07/2018 @ 07:48
Source : Dow Jones News
Stock : Ligand Pharmaceuticals Incorporated (LGND)
Quote : 114.47  0.0 (0.00%) @ 21:00
Ligand Pharmaceuticals Incorporated share price Chart

Ligand, Janssen Enter R&D Deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Historical Stock Chart

1 Year : From May 2018 to May 2019

Click Here for more Ligand Pharmaceuticals Incorporated Charts.
   Micah Maidenberg 

Subsidiaries of Ligand Pharmaceutical Inc. (LGND) and Johnson & Johnson (JNJ) have entered into a research-and-development agreement focused on a "transgenic chicken platform" aimed at generating and discovering antibodies for humans, according to a securities filing.

Ligand's company Crystal Bioscience Inc., and Janssen Research & Development LLC, which is part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, agreed to work together on Ligand's development of the platform, the filing said.

Under the deal, Ligand will be able to earn milestone payments contingent on various deliverables and will be able to sell the platform to others in the market.


Write to Micah Maidenberg at


(END) Dow Jones Newswires

July 11, 2018 17:33 ET (21:33 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Your Recent History
Euro vs Au..
US Dollar ..
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20190522 11:58:56